跳至主要内容
临床试验/NCT00174278
NCT00174278
已完成
3 期

Treatment With Recombinant Human Growth Hormone (Genotonorm®) In Children With Short Stature Secondary To A Long Term Corticoid Therapy. A Study of Efficacy and Safety.

Pfizer1 个研究点 分布在 1 个国家目标入组 14 人1997年2月

概览

阶段
3 期
干预措施
未指定
疾病 / 适应症
Growth Hormone Deficiency
发起方
Pfizer
入组人数
14
试验地点
1
主要终点
The main efficacy variable is the height SDS (SEMPE) before and after treatment.
状态
已完成
最后更新
17年前

概览

简要总结

To assess the effect of long-term treatment by Genotonorm on linear growth

注册库
clinicaltrials.gov
开始日期
1997年2月
结束日期
2006年10月
最后更新
17年前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

发起方
Pfizer

入排标准

入选标准

  • All the patients who have benefit during one year of a treatment by Genotonorm during the study 94-8123-014
  • All patients who have stopped during one year will be included if a signed written informed consent

排除标准

  • Endocrine disease, except well substituted hypothyroidism
  • Other severe chronic diseases (e.g. diabetes mellitus, cardiac or liver insufficiency)

结局指标

主要结局

The main efficacy variable is the height SDS (SEMPE) before and after treatment.

The standing height of the patients is measured during the inclusion visit and at each follow-up visit.

The height measurements are always performed at the same time of the day by

use of a wallmounted device (e.g. Harpenden Stadiometer).

Each child has to be measured three times, the mean of these measurements is recorded in the Case Report Form as the present height.

The body weight is measured by use of a balance scale.

Puberty stage is assessed (according to Tanner´s cotation) at the same visits as height is measured.

研究点 (1)

Loading locations...

相似试验